HepQuant's DuO test outperformed MELD and Child-Pugh scores in predicting esophageal varices risk, according to new data from the SHUNT-V and HALT-C studies.
Alpha Score of 43 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
The diagnostic landscape for compensated advanced chronic liver disease (cACLD) faces a significant shift following data presented at Digestive Disease Week (DDW) 2026. HepQuant’s oral presentation on May 5, 2026, established that the company’s proprietary Disease Severity Index (DSI)—derived from the Oral Cholate Challenge Test, or HepQuant DuO—demonstrated superior predictive power for esophageal varices risk compared to the industry-standard Child-Pugh (CP) and Model for End-Stage Liver Disease (MELD) scoring systems.
The clinical problem addressed by this data is the inherent limitation of current staging tools in early-stage liver disease. Child-Pugh and MELD scores are widely used for prognosis, but they often lack the granularity required to identify patients at risk for esophageal varices, particularly within the early CP A5 and A6 classifications. Dr. Mitchell Shiffman’s presentation, titled "The Disease Severity Index (DSI) from the Oral Cholate Challenge Test Defines Varices Risk Across Child-Pugh A5 and A6 and MASH Versus Non-MASH Etiologies," highlights that the DSI serves as a significant predictor where traditional scores fail to provide actionable clinical insight.
By utilizing the Oral Cholate Challenge Test, HepQuant DuO measures liver cell function and portal systemic shunting (SHUNT%) directly. This physiological approach contrasts with the static laboratory markers—such as bilirubin, albumin, and INR—that form the basis of MELD and CP scores. Because the DSI captures the dynamic interplay between liver function and blood flow, it offers a more precise characterization of liver physiology. This allows clinicians to better stratify patients who might otherwise be categorized identically under conventional scoring systems.
The findings are rooted in a robust analytical framework comparing the DSI, CP, and MELD scores against endoscopic findings. The analysis utilized data from two prospective US studies: SHUNT-V, which included 238 participants, and HALT-C, which included 216 participants. Researchers employed diagnostic performance metrics, specifically the area under the receiver operating characteristic (AUROC) curve, alongside multivariable logistic regression analysis.
Crucially, the study observed consistent results across both MASH (metabolic dysfunction-associated steatohepatitis) and non-MASH etiologies. This cross-etiology performance is vital for clinical adoption, as it suggests the DSI is a reliable indicator of portal hypertension regardless of the underlying cause of the liver disease. For practitioners, this means the test could potentially reduce the reliance on invasive endoscopic procedures for patients who do not demonstrate high-risk DSI profiles, while simultaneously identifying those who require urgent clinical intervention.
The shift toward noninvasive, blood-based diagnostics like HepQuant DuO represents a broader trend in stock market analysis regarding the commercialization of specialized diagnostic tools. By providing a quantitative baseline, the DSI allows for more rigorous monitoring of treatment effects over time. This is a departure from the current standard of care, which often relies on periodic, invasive endoscopies to assess varices risk.
For clinical management, the integration of DSI results into routine evaluation provides three distinct advantages:
It is important to note the regulatory status of the HepQuant DuO test. It is currently categorized as a Laboratory Developed Test (LDT), developed in accordance with CLIA requirements (CLIA ID 06D2188465). The test has not been cleared or approved by the U.S. Food and Drug Administration. While this does not preclude its use in clinical settings, it defines the current commercial boundary for the company. The presentation by Dr. Shiffman, a member of the HepQuant Portal Hypertension Group, was conducted without compensation, underscoring the academic focus of the data release.
As the hepatology community continues to seek alternatives to invasive procedures, the ability of the DSI to outperform established markers in the CP A5 and A6 cohorts provides a compelling case for its adoption. The next concrete marker for the company will be the broader integration of this data into clinical guidelines and the potential expansion of its prospective study data. Investors and clinicians should monitor how these findings influence the standard of care for patients with compensated advanced chronic liver disease, particularly as the industry moves toward more personalized, noninvasive diagnostic pathways.
AI-drafted from named sources and checked against AlphaScala publishing rules before release. Direct quotes must match source text, low-information tables are removed, and thinner or higher-risk stories can be held for manual review.